ParentID,ParentSMILES,FragmentSMILES,MetaText
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[4*]CC,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[5*]N1CCN([5*])CC1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[4*]C[8*],<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[14*]c1ccc([16*])cn1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[14*]c1ncc(F)c([14*])n1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[9*]n1c(C)nc2c(F)cc([16*])cc21,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,[8*]C(C)C,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA>
Abiraterone,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[1*]C(=O)C#CC,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[5*]N1CCCC1[13*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[14*]c1nc([14*])n2ccnc(N)c12,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[16*]c1ccc([16*])cc1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[1*]C([6*])=O,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[5*]N[5*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Acalabrutinib,CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,[14*]c1ccccn1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma> <TARGET=EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[8*]CC,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[1*]C(=O)C1c2cc3c(c(O)c2C(O[3*])CC1([15*])O)C(=O)c1c(O)cccc1C3=O,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[13*]C1CC([15*])C([15*])C(C)O1,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[5*]N(C)C,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[3*]O[3*],<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[13*]C1CC(O)C([15*])C(C)O1,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[3*]O[3*],<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[13*]C1CCC(=O)C(C)O1,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Aclarubicin,CCC1(O)CC(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)C1C(=O)OC,[3*]OC,<INDICATION=nan> <TARGET=TOP2A; SMN1; CSF2>
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[1*]C(=O)C(=C)F,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[5*]N1CCN([5*])C([13*])C1,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[5*]N1CCc2c([14*])nc([14*])nc2C1,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[3*]O[3*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[4*]C[8*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[13*]C1CCCN1C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[16*]c1cccc2cccc(Cl)c12,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Adagrasib,C=C(F)C(=O)N1CCN(c2nc(OCC3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)CC1CC#N,[8*]CC#N,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; GPM6B>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[5*]N(C)C,"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[4*]CC=[7*],"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[1*]C(=O)C=[7*],"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[5*]N[5*],"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[14*]c1ncnc2cc([16*])c([16*])cc12,"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[5*]N[5*],"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[16*]c1ccc(F)c(Cl)c1,"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[3*]O[3*],"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Afatinib,CN(C)CC=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC1CCOC1,[15*]C1CCOC1,"<INDICATION=Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer> <TARGET=NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO>"
Alectinib,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,[8*]CC,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF>"
Alectinib,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,[16*]c1cc2c(cc1[16*])C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF>"
Alectinib,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,[5*]N1CCC([15*])CC1,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF>"
Alectinib,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,[5*]N1CCOCC1,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF>"
Alitretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=[7*])C,<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alitretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC1=C(C)CCCC1(C)C,<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alitretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC=[7*],<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alitretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=[7*])C,<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alitretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=O)O,<INDICATION=AIDS-related Kaposi's Sarcoma> <TARGET=RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[14*]c1nc(C)c([14*])s1,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[5*]N[5*],<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[1*]C([1*])=O,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[5*]N1CCCC1[13*],<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[6*]C(N)=O,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[14*]c1cc([16*])ccn1,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Alpelisib,Cc1nc(NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,[8*]C(C)(C)C(F)(F)F,<INDICATION=Advanced Metastatic Breast Cancer> <TARGET=F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS>
Altretamine,CN(C)c1nc(N(C)C)nc(N(C)C)n1,[5*]N(C)C,<INDICATION=Ovarian Cancer; Ovarian Cancer Stage III> <TARGET=CYP1A2>
Altretamine,CN(C)c1nc(N(C)C)nc(N(C)C)n1,[14*]c1nc([14*])nc([14*])n1,<INDICATION=Ovarian Cancer; Ovarian Cancer Stage III> <TARGET=CYP1A2>
Altretamine,CN(C)c1nc(N(C)C)nc(N(C)C)n1,[5*]N(C)C,<INDICATION=Ovarian Cancer; Ovarian Cancer Stage III> <TARGET=CYP1A2>
Altretamine,CN(C)c1nc(N(C)C)nc(N(C)C)n1,[5*]N(C)C,<INDICATION=Ovarian Cancer; Ovarian Cancer Stage III> <TARGET=CYP1A2>
Aminolevulinic Acid,NCC(=O)CCC(=O)O,NCC(=O)CCC(=O)O,<INDICATION=Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC)> <TARGET=BCL2>
Amrubicin,CC(=O)C1(N)Cc2c(O)c3c(c(O)c2C(OC2CC(O)C(O)CO2)C1)C(=O)c1ccccc1C3=O,[6*]C(C)=O,<INDICATION=nan> <TARGET=TOP2A>
Amrubicin,CC(=O)C1(N)Cc2c(O)c3c(c(O)c2C(OC2CC(O)C(O)CO2)C1)C(=O)c1ccccc1C3=O,[3*]OC1CC([15*])(N)Cc2c(O)c3c(c(O)c21)C(=O)c1ccccc1C3=O,<INDICATION=nan> <TARGET=TOP2A>
Amrubicin,CC(=O)C1(N)Cc2c(O)c3c(c(O)c2C(OC2CC(O)C(O)CO2)C1)C(=O)c1ccccc1C3=O,[13*]C1CC(O)C(O)CO1,<INDICATION=nan> <TARGET=TOP2A>
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[3*]OC,"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[16*]c1ccc([16*])c([16*])c1,"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[5*]N[5*],"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[12*]S(C)(=O)=O,"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[5*]N[5*],"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,[16*]c1c2ccccc2nc2ccccc12,"<INDICATION=Leukemia, Acute; Refractory Leukemia> <TARGET=TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2>"
Anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,[8*]C(C)(C)C#N,"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,[16*]c1cc([16*])cc([16*])c1,"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,[8*]C[8*],"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,[9*]n1cncn1,"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,[8*]C(C)(C)C#N,"<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer> <TARGET=ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD>"
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[5*]NC,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[1*]C([6*])=O,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[16*]c1ccc([16*])c(F)c1,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[5*]N1C(=S)N([10*])C(=O)C12CCC2,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[16*]c1cnc(C#N)c([16*])c1,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Apalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,[8*]C(F)(F)F,<INDICATION=Nonmetastatic Prostate Cancer> <TARGET=AR; BEVI>
Arsenic Trioxide,[As+3].[As+3].[O-2].[O-2].[O-2],[As+3],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Arsenic Trioxide,[As+3].[As+3].[O-2].[O-2].[O-2],[As+3],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Arsenic Trioxide,[As+3].[As+3].[O-2].[O-2].[O-2],[O-2],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Arsenic Trioxide,[As+3].[As+3].[O-2].[O-2].[O-2],[O-2],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Arsenic Trioxide,[As+3].[As+3].[O-2].[O-2].[O-2],[O-2],<INDICATION=Refractory Acute Promyelocytic Leukemia> <TARGET=RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[1*]C([6*])=O,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[5*]N[5*],<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[16*]c1ccc([16*])cc1,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[3*]OC(F)(F)Cl,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[14*]c1ncc([16*])cc1[16*],<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[5*]N1CCC(O)C1,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Asciminib,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2ccn[nH]2)c1,[14*]c1ccn[nH]1,<INDICATION=Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase> <TARGET=ABL1; BCR>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[16*]c1cnn(C)c1,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[14*]c1ncnn2cc([16*])cc12,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[5*]N1CCN([5*])CC1,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[14*]c1ncc([16*])cn1,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[8*]C([8*])(C)N,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Avapritinib,Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,[16*]c1ccc(F)cc1,<INDICATION=Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=KIT; PDGFRA; FLT3; DPT; CBL>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[5*]NC,<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[1*]C([6*])=O,<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[16*]c1ccccc1[16*],<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[11*]S[11*],<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[7*]=Cc1n[nH]c2cc([16*])ccc12,<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Axitinib,CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1,[7*]=Cc1ccccn1,<INDICATION=Advanced Thyroid cancer> <TARGET=KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4>
Azacitidine,Nc1ncn(C2OC(CO)C(O)C2O)c(=O)n1,[9*]n1cnc(N)nc1=O,<INDICATION=Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia> <TARGET=NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11>
Azacitidine,Nc1ncn(C2OC(CO)C(O)C2O)c(=O)n1,[13*]C1OC([13*])C(O)C1O,<INDICATION=Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia> <TARGET=NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11>
Azacitidine,Nc1ncn(C2OC(CO)C(O)C2O)c(=O)n1,[8*]CO,<INDICATION=Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia> <TARGET=NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11>
Belinostat,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,[7*]=CC(=O)NO,<INDICATION=Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2>
Belinostat,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,[7*]=Cc1cccc(S([12*])(=O)=O)c1,<INDICATION=Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2>
Belinostat,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,[5*]N[5*],<INDICATION=Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2>
Belinostat,O=C(C=Cc1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,[16*]c1ccccc1,<INDICATION=Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2>
Belotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,[16*]c1c2c(nc3ccccc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,<INDICATION=nan> <TARGET=TOP1>
Belotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,[4*]CC[8*],<INDICATION=nan> <TARGET=TOP1>
Belotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,[5*]N[5*],<INDICATION=nan> <TARGET=TOP1>
Belotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,[4*]C(C)C,<INDICATION=nan> <TARGET=TOP1>
Belzutifan,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(O)C(F)C2F,[16*]c1ccc(S(C)(=O)=O)c2c1C(F)C(F)C2O,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=HMGB2>
Belzutifan,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(O)C(F)C2F,[3*]O[3*],<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=HMGB2>
Belzutifan,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(O)C(F)C2F,[16*]c1cc(F)cc(C#N)c1,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=HMGB2>
Bendamustine,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,[14*]c1nc2cc([16*])ccc2n1C,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bendamustine,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,[8*]CCCC(=O)O,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bendamustine,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,[5*]N([5*])[5*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bendamustine,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,[4*]CCCl,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bendamustine,Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,[4*]CCCl,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma> <TARGET=ATM; TP53; CD69>
Bexarotene,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,[16*]c1ccc(C(=C)c2cc3c(cc2C)C(C)(C)CCC3(C)C)cc1,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1>
Bexarotene,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,[6*]C(=O)O,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1>
Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,[1*]C(=O)C(C)(O)CS(=O)(=O)c1ccc(F)cc1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI>
Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI>
Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,[16*]c1ccc(C#N)c([16*])c1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI>
Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,[8*]C(F)(F)F,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI>
Binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,[16*]c1cc2c(ncn2C)c(F)c1[16*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,[16*]c1ccc(Br)cc1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,[3*]ONC([6*])=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,[4*]CCO,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5>
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[14*]c1nc([14*])c(C)c(N)n1,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[4*]C([8*])CC(N)=O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[4*]CC(N)C(N)=O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C([6*])=O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C(=O)C([4*])C([4*])[8*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C(=O)C(C)C(O)C([4*])C,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C(=O)C([4*])C(C)O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[4*]CC[8*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[14*]c1csc([14*])n1,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[14*]c1csc([14*])n1,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C([6*])=O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[5*]N[5*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[4*]CCC[S+](C)C,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[3*]O[3*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[13*]C1OC([13*])C(O)C(O)C1[15*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[8*]CO,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[3*]O[3*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[13*]C1OC([13*])C(O)C([15*])C1O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[8*]CO,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[3*]O[3*],"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[1*]C(N)=O,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bleomycin,Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1,[14*]c1cnc[nH]1,"<INDICATION=Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma> <TARGET=CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP>"
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[4*]C(CC(C)C)B(O)O,<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[5*]N[5*],<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[1*]C(=O)C([4*])C[8*],<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[16*]c1ccccc1,<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[5*]N[5*],<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[1*]C([6*])=O,<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bortezomib,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,[14*]c1cnccn1,<INDICATION=Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)> <TARGET=PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3>
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[3*]OC,"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[16*]c1cc([16*])c(Cl)cc1Cl,"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[5*]N[5*],"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[16*]c1cc2ncc(C#N)c([16*])c2cc1[16*],"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[3*]O[3*],"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[4*]CCC[4*],"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[5*]N1CCN(C)CC1,"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Bosutinib,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,[3*]OC,"<INDICATION=Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia> <TARGET=EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1>"
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[3*]OC,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[16*]c1ccc([16*])c([16*])c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[5*]N1CCC([15*])CC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[5*]N1CCN(C)CC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[14*]c1ncc(Cl)c([14*])n1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Brigatinib,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,[16*]c1ccccc1P(C)(C)=O,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[4*]CC,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N1CCCC1[13*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CCCN=C(N)N,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[4*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[3*]O[3*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[4*]C(C)(C)C,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1ccc(O)cc1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CO,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1c[nH]c2ccccc12,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[14*]c1cnc[nH]1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Buserelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[13*]C1CCC(=O)N1,<INDICATION=Stage D2 Prostatic carcinoma> <TARGET=GNRHR; IGFBP1>
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,[3*]OS(C)(=O)=O,<INDICATION=Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia> <TARGET=GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG>
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,[4*]CCCC[4*],<INDICATION=Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia> <TARGET=GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG>
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,[3*]OS(C)(=O)=O,<INDICATION=Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia> <TARGET=GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG>
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]OC,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[15*]C1CC2(O)C([15*])C3C4([15*])COC4CC([15*])C3(C)C(=O)C([15*])C(=C1C)C2(C)C,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]OC,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[1*]C(C)=O,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[1*]C([6*])=O,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[1*]C(=O)C(O)C([4*])[8*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[5*]N[5*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[1*]C([1*])=O,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[4*]C(C)(C)C,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabazitaxel,COC1C(=O)C2(C)C(OC)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,"<INDICATION=Refractory, metastatic hormone-refractory Prostate cancer> <TARGET=TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[3*]OC,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[16*]c1cc2nccc([16*])c2cc1[16*],"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[3*]O[3*],"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[16*]c1ccc([16*])cc1,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[5*]N[5*],"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[1*]C([6*])=O,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[15*]C1([15*])CC1,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[1*]C([6*])=O,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[5*]N[5*],"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[16*]c1ccc(F)cc1,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,[3*]OC,"<INDICATION=Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer> <TARGET=MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[4*]CCCCC,"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[3*]O[3*],"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[1*]C([1*])=O,"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[5*]N[5*],"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[9*]n1cc(F)c([14*])nc1=O,"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capecitabine,CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F,[13*]C1OC(C)C(O)C1O,"<INDICATION=Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma> <TARGET=MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[5*]N1CCC([15*])(N)CC1,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[1*]C([6*])=O,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[5*]N[5*],"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[4*]C([8*])CCO,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[16*]c1ccc(Cl)cc1,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capivasertib,NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,[14*]c1ncnc2[nH]ccc12,"<INDICATION=Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer> <TARGET=CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1>"
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[5*]NC,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[1*]C([6*])=O,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[16*]c1ccc([16*])c(F)c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[14*]c1cnc2ncc([14*])n2n1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[8*]C[8*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Capmatinib,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,[16*]c1ccc2ncccc2c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=DRD4; MET; PTEN>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[6*]C(=O)O,<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[15*]C1([15*])CCC1,<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[6*]C(=O)O,<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[NH2-],<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[NH2-],<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carboplatin,O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2],[Pt+2],<INDICATION=Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma> <TARGET=MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[5*]N[5*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[1*]C(=O)C([4*])CC[8*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[16*]c1ccccc1,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[5*]N[5*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[1*]C(=O)C[4*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[5*]N1CCOCC1,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[5*]N[5*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[1*]C(=O)C([4*])C[8*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[16*]c1ccccc1,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[5*]N[5*],<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[4*]C(CC(C)C)C([6*])=O,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carfilzomib,CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,[13*]C1(C)CO1,<INDICATION=Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM)> <TARGET=PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5>
Carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,[4*]CCCCCC,<INDICATION=nan> <TARGET=CYP3A4>
Carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,[5*]N[5*],<INDICATION=nan> <TARGET=CYP3A4>
Carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,[1*]C(=O)n1cc(F)c(=O)[nH]c1=O,<INDICATION=nan> <TARGET=CYP3A4>
Carmustine,O=NN(CCCl)C(=O)NCCCl,[1*]C(=O)N(CCCl)N=O,<INDICATION=Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma> <TARGET=MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4>
Carmustine,O=NN(CCCl)C(=O)NCCCl,[5*]N[5*],<INDICATION=Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma> <TARGET=MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4>
Carmustine,O=NN(CCCl)C(=O)NCCCl,[4*]CCCl,<INDICATION=Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma> <TARGET=MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4>
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[16*]c1cc([16*])c(C)cc1[16*],"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[5*]N[5*],"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[14*]c1ncc(Cl)c([14*])n1,"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[5*]N[5*],"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[16*]c1ccccc1S(=O)(=O)C(C)C,"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[3*]O[3*],"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[4*]C(C)C,"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Ceritinib,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,[15*]C1CCNCC1,"<INDICATION=Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR>"
Chlorambucil,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,[8*]CCCC(=O)O,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Chlorambucil,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Chlorambucil,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,[5*]N([5*])[5*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Chlorambucil,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,[4*]CCCl,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Chlorambucil,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,[4*]CCCl,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma> <TARGET=ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12>
Cisplatin,Cl[Pt]Cl.N.N,Cl[Pt]Cl,"<INDICATION=Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma> <TARGET=CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274>"
Cisplatin,Cl[Pt]Cl.N.N,N,"<INDICATION=Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma> <TARGET=CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274>"
Cisplatin,Cl[Pt]Cl.N.N,N,"<INDICATION=Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma> <TARGET=CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274>"
Cladribine,Nc1nc(Cl)nc2c1ncn2C1CC(O)C(CO)O1,[9*]n1cnc2c(N)nc(Cl)nc21,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL)> <TARGET=DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2>
Cladribine,Nc1nc(Cl)nc2c1ncn2C1CC(O)C(CO)O1,[13*]C1CC(O)C([13*])O1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL)> <TARGET=DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2>
Cladribine,Nc1nc(Cl)nc2c1ncn2C1CC(O)C(CO)O1,[8*]CO,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL)> <TARGET=DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2>
Clofarabine,Nc1nc(Cl)nc2c1ncn2C1OC(CO)C(O)C1F,[9*]n1cnc2c(N)nc(Cl)nc21,<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis> <TARGET=RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1>
Clofarabine,Nc1nc(Cl)nc2c1ncn2C1OC(CO)C(O)C1F,[13*]C1OC([13*])C(F)C1O,<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis> <TARGET=RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1>
Clofarabine,Nc1nc(Cl)nc2c1ncn2C1OC(CO)C(O)C1F,[8*]CO,<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis> <TARGET=RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[1*]C([6*])=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[16*]c1ccc(F)c(F)c1[16*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[16*]c1ccc(I)cc1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[5*]N1CC([15*])(O)C1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Cobimetinib,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,[13*]C1CCCCN1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[3*]OC,<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[6*]C(=O)N=c1nc2c([16*])c([16*])ccc2c2n1CCN2,<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[3*]O[3*],<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[4*]CCC[4*],<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[5*]N1CCOCC1,<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Copanlisib,COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(N)nc4)nc12)CCN3,[16*]c1cnc(N)nc1,<INDICATION=Relapsed Follicular Lymphoma> <TARGET=PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[4*]C([8*])C,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[3*]O[3*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[16*]c1cnc(N)c([16*])c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[9*]n1cc([16*])cn1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[15*]C1CCNCC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Crizotinib,CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,[16*]c1c(Cl)ccc(F)c1Cl,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR>
Cyclophosphamide,O=P1(N(CCCl)CCCl)NCCCO1,O=P1(N(CCCl)CCCl)NCCCO1,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor> <TARGET=EHMT2>"
Cytarabine,Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1,[9*]n1ccc(N)nc1=O,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia> <TARGET=ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251>
Cytarabine,Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1,[13*]C1OC([13*])C(O)C1O,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia> <TARGET=ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251>
Cytarabine,Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1,[8*]CO,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia> <TARGET=ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[8*]C(C)(C)C,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[14*]c1nc([14*])c([14*])s1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[16*]c1cccc([16*])c1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[12*]S(=O)(=O)c1c(F)cccc1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dabrafenib,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,[14*]c1ccnc(N)n1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2>
Dacarbazine,CN(C)N=Nc1nc[nH]c1C(N)=O,[14*]c1[nH]cnc1N=NN(C)C,"<INDICATION=Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor> <TARGET=ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU>"
Dacarbazine,CN(C)N=Nc1nc[nH]c1C(N)=O,[6*]C(N)=O,"<INDICATION=Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor> <TARGET=ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU>"
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[3*]OC,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[14*]c1ncnc2cc([16*])c([16*])cc12,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[16*]c1ccc(F)c(Cl)c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[1*]C(=O)C=[7*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[4*]CC=[7*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,[5*]N1CCCCC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2>
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[16*]c1c2nc3c([16*])ccc(C)c3oc-2c(C)c(=O)c1N,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[1*]C([6*])=O,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[5*]N[5*],"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[13*]C1NC(=O)C([15*])C(C)OC(=O)C([13*])N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[8*]C(C)C,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[8*]C(C)C,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[1*]C([6*])=O,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[5*]N[5*],"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[13*]C1NC(=O)C([15*])C(C)OC(=O)C([13*])N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[8*]C(C)C,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Dactinomycin,Cc1c2oc3c(C)ccc(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)c3nc-2c(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c(N)c1=O,[8*]C(C)C,"<INDICATION=Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer> <TARGET=CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT>"
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[4*]C(C)C[8*],<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[9*]n1ccc([14*])n1,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[16*]c1ccc(C#N)c(Cl)c1,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[5*]N[5*],<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[1*]C([6*])=O,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[14*]c1cc([14*])[nH]n1,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Darolutamide,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,[8*]C(C)O,<INDICATION=Non-mestatatic castrate-resistant prostate cancer> <TARGET=AR; BEVI>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[14*]c1cc([14*])nc(C)n1,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[5*]N[5*],<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[14*]c1cnc([14*])s1,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[1*]C([6*])=O,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[5*]N[5*],<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[16*]c1c(C)cccc1Cl,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[5*]N1CCN([5*])CC1,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,[4*]CCO,<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)> <TARGET=TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3>
Daunorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1,[3*]OC,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia> <TARGET=MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM>
Daunorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1c([16*])cccc1C3=O,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia> <TARGET=MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM>
Daunorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1,[6*]C(C)=O,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia> <TARGET=MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM>
Daunorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1,[13*]C1CC(N)C(O)C(C)O1,<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia> <TARGET=MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM>
Decitabine,Nc1ncn(C2CC(O)C(CO)O2)c(=O)n1,[9*]n1cnc(N)nc1=O,<INDICATION=Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS)> <TARGET=DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA>
Decitabine,Nc1ncn(C2CC(O)C(CO)O2)c(=O)n1,[13*]C1CC(O)C([13*])O1,<INDICATION=Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS)> <TARGET=DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA>
Decitabine,Nc1ncn(C2CC(O)C(CO)O2)c(=O)n1,[8*]CO,<INDICATION=Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS)> <TARGET=DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(C)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[16*]c1ccc2ccccc2c1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[16*]c1ccc(Cl)cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[16*]c1cccnc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])CO,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[16*]c1ccc([16*])cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[13*]C1CC(=O)NC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[16*]c1ccc([16*])cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(N)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C(=O)C([4*])CCCC[4*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[4*]C(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N1CCCC1[13*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Degarelix,CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,[4*]C(C)C(N)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,[15*]C1(O)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC21C,"<INDICATION=Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF)> <TARGET=NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA>"
Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,[6*]C(=O)CO,"<INDICATION=Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF)> <TARGET=NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA>"
Diethylstilbestrol,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,[7*]=C(CC)c1ccc(O)cc1,<INDICATION=nan> <TARGET=BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1>
Diethylstilbestrol,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,[7*]=C(CC)c1ccc(O)cc1,<INDICATION=nan> <TARGET=BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1>
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[1*]C(C)=O,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[3*]O[3*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[15*]C1CC2(O)C([15*])C3C4([15*])COC4CC(O)C3(C)C(=O)C(O)C(=C1C)C2(C)C,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[3*]O[3*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[1*]C(=O)C(O)C([4*])[8*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[5*]N[5*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[1*]C([1*])=O,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[3*]O[3*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[4*]C(C)(C)C,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[16*]c1ccccc1,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[3*]O[3*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[1*]C([6*])=O,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,[16*]c1ccccc1,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer> <TARGET=TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3>"
Doxorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma> <TARGET=ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A>"
Doxorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1c([16*])cccc1C3=O,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma> <TARGET=ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A>"
Doxorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[6*]C(=O)CO,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma> <TARGET=ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A>"
Doxorubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[13*]C1CC(N)C(O)C(C)O1,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma> <TARGET=ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A>"
Duvelisib,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,[4*]C([8*])C,"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Duvelisib,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,[5*]N[5*],"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Duvelisib,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,[14*]c1ncnc2nc[nH]c12,"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Duvelisib,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,[9*]n1c([14*])cc2cccc(Cl)c2c1=O,"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Duvelisib,CC(Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,[16*]c1ccccc1,"<INDICATION=Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma> <TARGET=F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R>"
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[4*]C(CO)C(C)O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[5*]N[5*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[1*]C([6*])=O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[13*]C1CSSCC([15*])C(=O)NC([13*])C(=O)NC([13*])C(=O)NC([13*])C(=O)NC([13*])C(=O)N1,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[5*]N[5*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[16*]c1ccccc1,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[5*]N[5*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[1*]C(=O)C[4*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[5*]N1CCN([5*])CCN([5*])CCN([5*])CC1,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[4*]CC(=O)O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[4*]CC(=O)O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[4*]CC(=O)O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[8*]C[8*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[16*]c1ccc(O)cc1,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[8*]C[8*],<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[16*]c1c[nH]c2ccccc12,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[8*]CCCCN,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Edotreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,[8*]C(C)O,<INDICATION=Neuroendocrine Tumors> <TARGET=FASLG>
Eflornithine,NCCCC(N)(C(=O)O)C(F)F,NCCCC(N)(C(=O)O)C(F)F,<INDICATION=High Risk Neuroblastoma> <TARGET=XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX>
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[4*]CC,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[5*]N[5*],"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[4*]CC[8*],"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[16*]c1ccc([16*])cc1,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[4*]C[8*],"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[5*]N([5*])[5*],"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[4*]CC,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[16*]c1ccc([16*])c([16*])c1,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[3*]OC,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Elacestrant,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,[15*]C1CCc2cc(O)ccc2C1,"<INDICATION=Advanced Breast Cancer, Metastatic Breast Cancer> <TARGET=ESR1; ERBB2>"
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[4*]CC(C)(C)O,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[5*]N[5*],<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[14*]c1nc([14*])nc([14*])n1,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[5*]N[5*],<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[14*]c1cc([16*])ccn1,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[8*]C(F)(F)F,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[14*]c1cccc([14*])n1,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,[8*]C(F)(F)F,<INDICATION=Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH2; FLT3; GRB2; IDH1>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[3*]OC,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[1*]C([1*])=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[4*]CC([4*])C,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[14*]c1ccnc([14*])n1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[9*]n1cc([16*])c([14*])n1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[8*]C(C)C,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[16*]c1cc(Cl)cc([16*])c1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Encorafenib,COC(=O)NC(C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,[12*]S(C)(=O)=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma> <TARGET=KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN>
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[5*]N1CCN(C)CC1,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[16*]c1ccc([16*])c([16*])c1,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[1*]C([6*])=O,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[5*]N[5*],"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[14*]c1n[nH]c2ccc([16*])cc12,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[8*]C[8*],"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[16*]c1cc(F)cc(F)c1,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[5*]N[5*],"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Entrectinib,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,[15*]C1CCOCC1,"<INDICATION=Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid> <TARGET=NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN>"
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[5*]NC,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[1*]C([6*])=O,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[16*]c1ccc([16*])c(F)c1,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[5*]N1C(=S)N([10*])C(=O)C1(C)C,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[16*]c1ccc(C#N)c([16*])c1,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,[8*]C(F)(F)F,<INDICATION=Metastatic Castration Resistant Prostate Cancer> <TARGET=BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR>
Epirubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[3*]OC,<INDICATION=Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder> <TARGET=TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2>
Epirubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1c([16*])cccc1C3=O,<INDICATION=Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder> <TARGET=TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2>
Epirubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[6*]C(=O)CO,<INDICATION=Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder> <TARGET=TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2>
Epirubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1,[13*]C1CC(N)C(O)C(C)O1,<INDICATION=Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder> <TARGET=TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2>
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[3*]OC,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[16*]c1cc([16*])cc([16*])c1,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[3*]OC,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[5*]N([5*])[5*],"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[4*]CC[4*],"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[5*]N[5*],"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[4*]C(C)C,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[14*]c1cnc2ccc([16*])cc2n1,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Erdafitinib,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,[16*]c1cnn(C)c1,"<INDICATION=Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma> <TARGET=SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4>"
Eribulin,C=C1CC2CCC34CC5OC6C(OC7CCC(CC(=O)CC8C(CC9OC(CCC1O2)CC(C)C9=C)OC(CC(O)CN)C8OC)OC7C6O3)C5O4,[13*]C1OC2CC3OC(CCC4OC(CCC56CC7OC8C(OC9CCC(CC(=O)CC2C1[15*])OC9C8O5)C7O6)CC4=C)CC(C)C3=C,"<INDICATION=Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma> <TARGET=TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2>"
Eribulin,C=C1CC2CCC34CC5OC6C(OC7CCC(CC(=O)CC8C(CC9OC(CCC1O2)CC(C)C9=C)OC(CC(O)CN)C8OC)OC7C6O3)C5O4,[8*]CC(O)CN,"<INDICATION=Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma> <TARGET=TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2>"
Eribulin,C=C1CC2CCC34CC5OC6C(OC7CCC(CC(=O)CC8C(CC9OC(CCC1O2)CC(C)C9=C)OC(CC(O)CN)C8OC)OC7C6O3)C5O4,[3*]OC,"<INDICATION=Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma> <TARGET=TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2>"
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[16*]c1cccc(C#C)c1,<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[5*]N[5*],<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[14*]c1ncnc2cc([16*])c([16*])cc12,<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[3*]O[3*],<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[4*]CC[4*],<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[3*]OC,<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[3*]O[3*],<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[4*]CC[4*],<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,[3*]OC,<INDICATION=Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic> <TARGET=DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[16*]c1ccc2c(c1)CCC1C2CCC2(C)C(O)CCC12,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[3*]O[3*],<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[1*]C([1*])=O,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[5*]N([5*])[5*],<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[4*]CCCl,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Estramustine,CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,[4*]CCCl,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1>
Etoposide,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer> <TARGET=GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1>"
Etoposide,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,[3*]OC1c2cc3c(cc2C(c2cc([16*])c(O)c([16*])c2)C2C(=O)OCC12)OCO3,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer> <TARGET=GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1>"
Etoposide,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,[13*]C1OC2COC(C)OC2C(O)C1O,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer> <TARGET=GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1>"
Etoposide,COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer> <TARGET=GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[13*]C1CC(=O)C(C)C=C(C)C(O)C([15*])C(=O)C(C)CC(C)C=CC=CC=C(C)C([15*])CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)O1,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[8*]CC([8*])C,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[15*]C1CCC([15*])C([15*])C1,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]O[3*],"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[4*]CCO,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,"<INDICATION=Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors> <TARGET=PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET>"
Exemestane,C=C1CC2C(CCC3(C)C(=O)CCC23)C2(C)C=CC(=O)C=C12,C=C1CC2C(CCC3(C)C(=O)CCC23)C2(C)C=CC(=O)C=C12,"<INDICATION=Early Breast Cancer; Refractory, advanced Breast cancer> <TARGET=CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2>"
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[14*]c1ncc(C)c([14*])n1,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[5*]N[5*],<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[16*]c1ccc([16*])cc1,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[3*]O[3*],<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[4*]CC[4*],<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[5*]N1CCCC1,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[5*]N[5*],<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[12*]S(=O)(=O)c1cccc([16*])c1,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[5*]N[5*],<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,[4*]C(C)(C)C,<INDICATION=nan> <TARGET=JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1>
Fludarabine,Nc1nc(F)nc2c1ncn2C1OC(CO)C(O)C1O,[9*]n1cnc2c(N)nc(F)nc21,<INDICATION=B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma> <TARGET=MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40>
Fludarabine,Nc1nc(F)nc2c1ncn2C1OC(CO)C(O)C1O,[13*]C1OC([13*])C(O)C1O,<INDICATION=B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma> <TARGET=MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40>
Fludarabine,Nc1nc(F)nc2c1ncn2C1OC(CO)C(O)C1O,[8*]CO,<INDICATION=B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma> <TARGET=MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40>
Fluorouracil,O=c1[nH]cc(F)c(=O)[nH]1,O=c1[nH]cc(F)c(=O)[nH]1,<INDICATION=Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma> <TARGET=OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1>
Fluoxymesterone,CC1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3(F)C(O)CC21C,CC1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3(F)C(O)CC21C,"<INDICATION=Inoperable, metastatic Breast cancer> <TARGET=AR; NR3C1; BEVI; PRL>"
Flutamide,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,[1*]C(=O)C(C)C,<INDICATION=C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma> <TARGET=CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A>
Flutamide,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,[5*]N[5*],<INDICATION=C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma> <TARGET=CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A>
Flutamide,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,[16*]c1ccc([N+](=O)[O-])c([16*])c1,<INDICATION=C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma> <TARGET=CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A>
Flutamide,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,[8*]C(F)(F)F,<INDICATION=C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma> <TARGET=CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A>
Fotemustine,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,[4*]CC,<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fotemustine,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,[3*]OP(=O)(O[3*])C([4*])C,<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fotemustine,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,[4*]CC,<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fotemustine,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,[5*]N[5*],<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fotemustine,CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O,[1*]C(=O)N(CCCl)N=O,<INDICATION=Metastatic Melanoma> <TARGET=MGMT; TXNRD1>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[5*]NC,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[1*]C([6*])=O,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[16*]c1ccc2c([16*])c(C)oc2c1,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[3*]O[3*],<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[14*]c1ncnc2cc([16*])c([16*])cc12,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[3*]OC,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,[3*]OC,<INDICATION=Metastatic Colorectal Cancer> <TARGET=KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS>
Fulvestrant,CC12CCC3c4ccc(O)cc4CC(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3C1CCC2O,[15*]C1Cc2cc(O)ccc2C2CCC3(C)C(O)CCC3C12,"<INDICATION=Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF>"
Fulvestrant,CC12CCC3c4ccc(O)cc4CC(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)C3C1CCC2O,[8*]CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F,"<INDICATION=Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF>"
Futibatinib,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,[1*]C(=O)C=C,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Futibatinib,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,[5*]N1CCC([15*])C1,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Futibatinib,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,[9*]n1nc(C#Cc2cc([16*])cc([16*])c2)c2c(N)ncnc21,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Futibatinib,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,[3*]OC,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Futibatinib,C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,[3*]OC,"<INDICATION=Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma> <TARGET=NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3>"
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[3*]OC,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[14*]c1ncnc2cc([16*])c([16*])cc12,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[16*]c1ccc(F)c(Cl)c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[3*]O[3*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[4*]CCC[4*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,[5*]N1CCOCC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1>
Gemcitabine,Nc1ccn(C2OC(CO)C(O)C2(F)F)c(=O)n1,[9*]n1ccc(N)nc1=O,"<INDICATION=Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma> <TARGET=C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1>"
Gemcitabine,Nc1ccn(C2OC(CO)C(O)C2(F)F)c(=O)n1,[13*]C1OC([13*])C(F)(F)C1O,"<INDICATION=Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma> <TARGET=C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1>"
Gemcitabine,Nc1ccn(C2OC(CO)C(O)C2(F)F)c(=O)n1,[8*]CO,"<INDICATION=Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma> <TARGET=C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1>"
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[8*]CC,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[14*]c1nc([14*])c([14*])nc1[14*],<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[6*]C(N)=O,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[5*]N[5*],<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[16*]c1ccc([16*])c([16*])c1,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[5*]N1CCC([15*])CC1,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[5*]N1CCN(C)CC1,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[3*]OC,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[5*]N[5*],<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,[15*]C1CCOCC1,<INDICATION=Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations> <TARGET=HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[13*]C1CC([15*])CCN1C,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[5*]N[5*],<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[1*]C([1*])=O,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[5*]N[5*],<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[16*]c1ccc(C#N)cc1,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Glasdegib,CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,[14*]c1nc2ccccc2[nH]1,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=SMO; ALOX12; MTOR; FLT3>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])C[4*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[3*]O[3*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[4*]C(C)(C)C,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[16*]c1ccc(O)cc1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])CO,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[16*]c1c[nH]c2ccccc12,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[14*]c1cnc[nH]1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C([6*])=O,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[13*]C1CCC(=O)N1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[1*]C(=O)C([4*])CCCN=C(N)N,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[5*]N1CCCC1[13*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Goserelin,CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,[6*]C(=O)NNC(N)=O,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate> <TARGET=ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR>
Histamine dihydrochloride,Cl.Cl.NCCc1cnc[nH]1,Cl,<INDICATION=Acute Myeloid Leukaemia> <TARGET=AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA>
Histamine dihydrochloride,Cl.Cl.NCCc1cnc[nH]1,Cl,<INDICATION=Acute Myeloid Leukaemia> <TARGET=AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA>
Histamine dihydrochloride,Cl.Cl.NCCc1cnc[nH]1,[8*]CCN,<INDICATION=Acute Myeloid Leukaemia> <TARGET=AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA>
Histamine dihydrochloride,Cl.Cl.NCCc1cnc[nH]1,[14*]c1cnc[nH]1,<INDICATION=Acute Myeloid Leukaemia> <TARGET=AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[4*]CC,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N1CCCC1[13*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CCCN=C(N)N,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[9*]n1cnc([14*])c1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[8*]C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1ccccc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1ccc(O)cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CO,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1c[nH]c2ccccc12,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[14*]c1cnc[nH]1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Histrelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1cn(Cc2ccccc2)cn1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[13*]C1CCC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; GNRHR2>
Hydroxyurea,NC(=O)NO,NC(=O)NO,"<INDICATION=Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer> <TARGET=BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT>"
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[1*]C(=O)C=C,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[5*]N1CCCC([15*])C1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[9*]n1nc([14*])c2c(N)ncnc21,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[16*]c1ccc([16*])cc1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[3*]O[3*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Ibrutinib,C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,[16*]c1ccccc1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM)> <TARGET=CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2>
Idarubicin,CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O,[6*]C(C)=O,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4>
Idarubicin,CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1ccccc1C3=O,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4>
Idarubicin,CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O,[13*]C1CC(N)C(O)C(C)O1,<INDICATION=Acute Myeloid Leukemia (AML)> <TARGET=CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4>
Idelalisib,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,[4*]C([8*])CC,<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Idelalisib,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,[5*]N[5*],<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Idelalisib,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,[14*]c1ncnc2nc[nH]c12,<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Idelalisib,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,[9*]n1c([14*])nc2cccc(F)c2c1=O,<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Idelalisib,CCC(Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,[16*]c1ccccc1,<INDICATION=Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma> <TARGET=PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R>
Ifosfamide,O=P1(NCCCl)OCCCN1CCCl,O=P1(NCCCl)OCCCN1CCCl,"<INDICATION=Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma> <TARGET=TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[16*]c1ccc(C)c([16*])c1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[5*]N[5*],"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[1*]C([6*])=O,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[16*]c1ccc([16*])cc1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[4*]C[8*],"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[5*]N1CCN(C)CC1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[5*]N[5*],"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[14*]c1ccnc([14*])n1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,[16*]c1cccnc1,"<INDICATION=Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor> <TARGET=KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT>"
Imiquimod,CC(C)Cn1cnc2c(N)nc3ccccc3c21,[8*]CC(C)C,<INDICATION=Superficial Basal Cell Carcinoma> <TARGET=TLR7; IFNA1; SARDH; GMNN>
Imiquimod,CC(C)Cn1cnc2c(N)nc3ccccc3c21,[9*]n1cnc2c(N)nc3ccccc3c21,<INDICATION=Superficial Basal Cell Carcinoma> <TARGET=TLR7; IFNA1; SARDH; GMNN>
Inavolisib,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,[4*]C(C)C(N)=O,<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Inavolisib,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,[5*]N[5*],<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Inavolisib,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,[14*]c1cn2c(n1)-c1ccc([16*])cc1OCC2,<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Inavolisib,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,[10*]N1C(=O)OCC1[13*],<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Inavolisib,CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,[8*]C(F)F,<INDICATION=Locally advanced or metastatic breast cancer> <TARGET=PIK3CG; FGFR2; PIK3CA>
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[4*]CC,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[5*]N1CCN([5*])CC1,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[16*]c1ccc([16*])cc1,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[5*]N[5*],"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[14*]c1cc([14*])ncn1,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[5*]N([5*])C,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[1*]C([1*])=O,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[5*]N[5*],"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[16*]c1cc([16*])c(Cl)c([16*])c1Cl,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[3*]OC,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Infigratinib,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,[3*]OC,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[4*]CCC,"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[5*]N([5*])[5*],"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[4*]CC[4*],"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[3*]O[3*],"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[16*]c1c(Cl)cc(Cl)cc1Cl,"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[1*]C(=O)n1ccnc1,"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],O=S(=O)([O-])C(I)I,"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Interferon Alfa-2b,CCCN(CCOc1c(Cl)cc(Cl)cc1Cl)C(=O)n1ccnc1.O=S(=O)([O-])C(I)I.[Na+],[Na+],"<INDICATION=Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant> <TARGET=IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX>"
Iobenguane I-131,NC(N)=NCc1cccc(I)c1,[8*]CN=C(N)N,"<INDICATION=Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas> <TARGET=SLC6A2; TH>"
Iobenguane I-131,NC(N)=NCc1cccc(I)c1,[16*]c1cccc(I)c1,"<INDICATION=Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas> <TARGET=SLC6A2; TH>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[8*]CC,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[16*]c1ccc2nc3c(c([16*])c2c1)Cn1c-3cc2c(c1=O)COC(=O)C2(O)CC,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[3*]O[3*],"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[1*]C([1*])=O,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[5*]N1CCC([15*])CC1,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Irinotecan,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,[5*]N1CCCCC1,"<INDICATION=Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma> <TARGET=RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[14*]c1cc(C#N)ccn1,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[10*]N1C(=O)CCC1[13*],"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[1*]C([6*])=O,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[5*]N([5*])[5*],"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[16*]c1cncc(F)c1,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[1*]C(=O)C([4*])[8*],"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[5*]N[5*],"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[15*]C1CC(F)(F)C1,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ivosidenib,N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,[16*]c1ccccc1Cl,"<INDICATION=Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation> <TARGET=IDH2; GPX1P2; IDH1>"
Ixabepilone,CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,[7*]=C(C)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1>
Ixabepilone,CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,[7*]=Cc1csc(C)n1,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[4*]C(CC(C)C)B(O)O,<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[5*]N[5*],<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[1*]C(=O)C[4*],<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[5*]N[5*],<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[1*]C([6*])=O,<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Ixazomib,CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,[16*]c1cc(Cl)ccc1Cl,<INDICATION=Multiple Myeloma (MM)> <TARGET=PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9>
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[8*]C(C)C,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[13*]C1CSSCC([15*])C(=O)NC([13*])C(=O)NC([13*])C(=O)NC([13*])C(=O)NC([13*])C(=O)N1,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[8*]CCCCN,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[8*]C[8*],"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[16*]c1c[nH]c2ccccc12,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[8*]C[8*],"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[16*]c1ccc(O)cc1,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[5*]N[5*],"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[1*]C(=O)C(N)C[8*],"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[16*]c1ccc2ccccc2c1,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[1*]C([6*])=O,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[5*]N[5*],"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lanreotide,CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,[4*]C(C(N)=O)C(C)O,"<INDICATION=Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors> <TARGET=SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[4*]CCS(C)(=O)=O,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[5*]N[5*],"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[4*]C[8*],"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[14*]c1ccc([14*])o1,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[14*]c1ncnc2ccc([16*])cc12,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[5*]N[5*],"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[16*]c1ccc([16*])c(Cl)c1,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3*]O[3*],"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[4*]C[8*],"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Lapatinib,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[16*]c1cccc(F)c1,"<INDICATION=Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1>"
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[1*]C([1*])=O,<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[5*]N[5*],<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[14*]c1ccn2ncc([16*])c2n1,<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[5*]N1CCCC1[13*],<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[16*]c1cc(F)ccc1F,<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Larotrectinib,O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,[5*]N1CCC(O)C1,<INDICATION=NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive> <TARGET=NTRK1; NTRK3; NTRK2; DRD5P1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[1*]C(=O)C=C,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[5*]N[5*],<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[16*]c1cc([16*])c([16*])cc1[16*],<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[5*]N[5*],<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[14*]c1ccnc([14*])n1,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[9*]n1cc([16*])c([14*])n1,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[4*]C[8*],<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[5*]N(C)C,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[16*]c1ccccc1,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[3*]OC,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lazertinib,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,[5*]N1CCOCC1,<INDICATION=First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)> <TARGET=EPHB3; DXO; EGFR; DRD2; FDX1>
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,[10*]N1Cc2c(N)cccc2C1=O,<INDICATION=Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma> <TARGET=TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2>
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,[15*]C1CCC(=O)NC1=O,<INDICATION=Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma> <TARGET=TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[16*]c1cc2nccc([16*])c2cc1[16*],<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[3*]O[3*],<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[16*]c1ccc([16*])c(Cl)c1,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[1*]C([1*])=O,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[15*]C1CC1,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,[6*]C(N)=O,<INDICATION=Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer> <TARGET=DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3>
Letrozole,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,[16*]c1ccc(C#N)cc1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer> <TARGET=CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613>
Letrozole,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,[8*]C([8*])[8*],<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer> <TARGET=CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613>
Letrozole,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,[16*]c1ccc(C#N)cc1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer> <TARGET=CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613>
Letrozole,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,[9*]n1cncn1,<INDICATION=Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer> <TARGET=CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[4*]CC,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N1CCCC1[13*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CCCN=C(N)N,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1ccc(O)cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])CO,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[16*]c1c[nH]c2ccccc12,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[14*]c1cnc[nH]1,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1,[13*]C1CCC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4>
Lomustine,O=NN(CCCl)C(=O)NC1CCCCC1,[1*]C(=O)N(CCCl)N=O,<INDICATION=Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain> <TARGET=IDH1; MGMT; ADK; EGFR>
Lomustine,O=NN(CCCl)C(=O)NC1CCCCC1,[5*]N[5*],<INDICATION=Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain> <TARGET=IDH1; MGMT; ADK; EGFR>
Lomustine,O=NN(CCCl)C(=O)NC1CCCCC1,[15*]C1CCCCC1,<INDICATION=Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain> <TARGET=IDH1; MGMT; ADK; EGFR>
Lorlatinib,CC1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,CC1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"<INDICATION=Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer> <TARGET=EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF>"
Lurbinectedin,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]OC,<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Lurbinectedin,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[16*]c1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c([16*])c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c([16*])c(O)c5C(C21)N3C)OCO4,<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Lurbinectedin,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]O[3*],<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Lurbinectedin,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[1*]C(C)=O,<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Lurbinectedin,COc1ccc2[nH]c3c(c2c1)CCNC31CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]OC,<INDICATION=Metastatic Small Cell Lung Cancer> <TARGET=nan>
Mechlorethamine,CN(CCCl)CCCl,[5*]N([5*])C,"<INDICATION=Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion> <TARGET=MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2>"
Mechlorethamine,CN(CCCl)CCCl,[4*]CCCl,"<INDICATION=Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion> <TARGET=MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2>"
Mechlorethamine,CN(CCCl)CCCl,[4*]CCCl,"<INDICATION=Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion> <TARGET=MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2>"
Medroxyprogesterone,CC(=O)C1(O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,[6*]C(C)=O,<INDICATION=Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma> <TARGET=BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5>
Medroxyprogesterone,CC(=O)C1(O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,[15*]C1(O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C,<INDICATION=Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma> <TARGET=BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5>
Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,[1*]C(C)=O,<INDICATION=Advanced Breast Cancer; Advanced Endometrial Cancer> <TARGET=ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2>
Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,[3*]O[3*],<INDICATION=Advanced Breast Cancer; Advanced Endometrial Cancer> <TARGET=ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2>
Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,[15*]C1([15*])CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,<INDICATION=Advanced Breast Cancer; Advanced Endometrial Cancer> <TARGET=ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2>
Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C,[6*]C(C)=O,<INDICATION=Advanced Breast Cancer; Advanced Endometrial Cancer> <TARGET=ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2>
Melphalan,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,[8*]CC(N)C(=O)O,<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,[16*]c1ccc([16*])cc1,<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,[5*]N([5*])[5*],<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,[4*]CCCl,<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan,NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,[4*]CCCl,<INDICATION=Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[4*]CC,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[3*]O[3*],<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[1*]C(=O)C([4*])C[8*],<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[16*]c1ccc(F)cc1,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[5*]N[5*],<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[1*]C(=O)C(N)C[8*],<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[5*]N([5*])[5*],<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[4*]CCCl,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Melphalan Flufenamide,CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1,[4*]CCCl,<INDICATION=Relapsed Or Refractory Multiple Myeloma> <TARGET=CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53>
Mercaptopurine,S=c1nc[nH]c2nc[nH]c12,S=c1nc[nH]c2nc[nH]c12,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic> <TARGET=IDH1; KDM4A; BAZ2B>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[5*]N([5*])C,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[4*]C[8*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[14*]c1cnc2nc(N)nc(N)c2n1,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[16*]c1ccc([16*])cc1,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[1*]C([6*])=O,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[5*]N[5*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[4*]C(CCC(=O)O)C(=O)O,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer> <TARGET=TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8>"
Midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,[3*]OC,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,[15*]C1CC2OC(C)(C1[15*])n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,[5*]N([5*])C,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,[1*]C([6*])=O,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Midostaurin,COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,[16*]c1ccccc1,<INDICATION=Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm> <TARGET=NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1>
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)CCCCCCCCCCCCCCC,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[3*]O[3*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[4*]CC([4*])C[4*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[3*]OP(=O)([O-])O[3*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[4*]CC[4*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[5*]N[5*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)C([4*])C,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[5*]N[5*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)CCC([4*])C(N)=O,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[5*]N[5*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)C([4*])C,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[5*]N[5*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)C([4*])C,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[3*]O[3*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[4*]C(C=O)C([4*])C(O)C(O)CO,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[5*]N[5*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(C)=O,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[3*]O[3*],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[1*]C(=O)CCCCCCCCCCCCCCC,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],O,"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mifamurtide,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCNC(=O)C(C)NC(=O)CCC(NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(C)=O)C(O)C(O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],[Na+],"<INDICATION=High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma> <TARGET=NOD2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]OC,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[15*]C1C=CC=C(C)Cc2cc([16*])c(Cl)c(c2)N(C)C(=O)CC([15*])C2(C)OC2C(C)C2CC1(O)NC(=O)O2,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]O[3*],"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[1*]C(=O)C([4*])C,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[5*]N([5*])C,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[1*]C(=O)CCC([4*])(C)C,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[11*]SS[11*],"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[4*]CCC(C(N)=O)S(=O)(=O)O,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mirvetuximab Soravtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(=O)(=O)O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]OC,"<INDICATION=Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer> <TARGET=HOXB2>"
Mitomycin,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,[3*]OC,"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitomycin,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,[15*]C1C2=C(C(=O)C(C)=C(N)C2=O)N2CC3NC3C12[15*],"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitomycin,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,[4*]C[8*],"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitomycin,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,[3*]O[3*],"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitomycin,COC12C(COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1CC1NC12,[1*]C(N)=O,"<INDICATION=Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)> <TARGET=IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[16*]c1ccc([16*])c2c1C(=O)c1c(O)ccc(O)c1C2=O,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[5*]N[5*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[4*]CC[4*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[5*]N[5*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[4*]CCO,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[5*]N[5*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[4*]CC[4*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[5*]N[5*],"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mitoxantrone,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,[4*]CCO,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma> <TARGET=UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[1*]C(=O)C=C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N[5*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[16*]c1cc([16*])c([16*])cc1[16*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N[5*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[14*]c1ncc([16*])c([14*])n1,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[1*]C([6*])=O,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[3*]O[3*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[4*]C(C)C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[16*]c1cn(C)c2ccccc12,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[3*]OC,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N([5*])C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[4*]CC[4*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Mobocertinib,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N(C)C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR>"
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(C)=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[15*]C1CC2(O)C([15*])C3C4([15*])COC4CC(O)C3(C)C(=O)C([15*])C(=C1C)C2(C)C,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(C)=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C([6*])=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(=O)C(O)C([4*])[8*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[5*]N[5*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C([6*])=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nab-Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Nelarabine,COc1nc(N)nc2c1ncn2C1OC(CO)C(O)C1O,[3*]OC,<INDICATION=Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia> <TARGET=POLA1; NT5C2>
Nelarabine,COc1nc(N)nc2c1ncn2C1OC(CO)C(O)C1O,[9*]n1cnc2c([14*])nc(N)nc21,<INDICATION=Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia> <TARGET=POLA1; NT5C2>
Nelarabine,COc1nc(N)nc2c1ncn2C1OC(CO)C(O)C1O,[13*]C1OC([13*])C(O)C1O,<INDICATION=Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia> <TARGET=POLA1; NT5C2>
Nelarabine,COc1nc(N)nc2c1ncn2C1OC(CO)C(O)C1O,[8*]CO,<INDICATION=Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia> <TARGET=POLA1; NT5C2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[4*]CC,<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[3*]O[3*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[16*]c1cc2ncc(C#N)c([16*])c2cc1[16*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[5*]N[5*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[16*]c1ccc([16*])c(Cl)c1,<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[3*]O[3*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[4*]C[8*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[14*]c1ccccn1,<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[5*]N[5*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[1*]C(=O)C=[7*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[4*]CC=[7*],<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,[5*]N(C)C,<INDICATION=Breast Cancer> <TARGET=KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2>
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[9*]n1cnc(C)c1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[16*]c1cc([16*])cc([16*])c1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[5*]N[5*],"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[1*]C([6*])=O,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[16*]c1ccc(C)c([16*])c1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[5*]N[5*],"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[14*]c1ccnc([14*])n1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[16*]c1cccnc1,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilotinib,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,[8*]C(F)(F)F,"<INDICATION=Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia> <TARGET=DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1>"
Nilutamide,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,[10*]N1C(=O)NC(C)(C)C1=O,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4>
Nilutamide,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,[16*]c1ccc([N+](=O)[O-])c([16*])c1,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4>
Nilutamide,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,[8*]C(F)(F)F,<INDICATION=Metastatic Hormone Refractory Prostate Cancer> <TARGET=KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[3*]OC,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[1*]C([6*])=O,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[16*]c1ccc(N=C(c2ccccc2)c2c(O)[nH]c3cc([16*])ccc23)cc1,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[5*]N([5*])C,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[1*]C(=O)C[4*],<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Nintedanib,COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,[5*]N1CCN(C)CC1,<INDICATION=Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma> <TARGET=FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET>
Niraparib,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,[6*]C(N)=O,<INDICATION=Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer> <TARGET=BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2>
Niraparib,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,[9*]n1cc2cccc([16*])c2n1,<INDICATION=Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer> <TARGET=BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2>
Niraparib,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,[16*]c1ccc([16*])cc1,<INDICATION=Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer> <TARGET=BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2>
Niraparib,NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,[15*]C1CCCNC1,<INDICATION=Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer> <TARGET=BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,Br,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,Br,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[1*]C(=O)C([4*])CCC,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[5*]N[5*],<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[15*]C1CCc2cc(F)cc(F)c2C1,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[5*]N[5*],<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[9*]n1cnc([14*])c1,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[4*]CC([8*])(C)C,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[5*]N[5*],<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Nirogacestat Hydrobromide,Br.Br.CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,[4*]CC(C)(C)C,<INDICATION=Progressive Desmoid Tumors> <TARGET=PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[1*]C([6*])=O,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[16*]c1ccc(F)c([16*])c1,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[8*]C[8*],<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[14*]c1n[nH]c(=O)c2ccccc12,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[5*]N1CCN([5*])CC1,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[1*]C([6*])=O,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olaparib,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,[15*]C1CC1,<INDICATION=Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer> <TARGET=PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3>
Olutasidenib,CC(Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,[4*]C([8*])C,"<INDICATION=Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH1; GPX1P2>"
Olutasidenib,CC(Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,[5*]N[5*],"<INDICATION=Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH1; GPX1P2>"
Olutasidenib,CC(Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,[16*]c1ccc(C#N)n(C)c1=O,"<INDICATION=Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH1; GPX1P2>"
Olutasidenib,CC(Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,[16*]c1cc2cc(Cl)ccc2[nH]c1=O,"<INDICATION=Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)> <TARGET=IDH1; GPX1P2>"
Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,[3*]OC,"<INDICATION=Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia> <TARGET=BIRC5; FLT3; TERT; BCR; ABL1>"
Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,[1*]C(=O)CC(O)(CCCC(C)(C)O)C([1*])=O,"<INDICATION=Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia> <TARGET=BIRC5; FLT3; TERT; BCR; ABL1>"
Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,[3*]O[3*],"<INDICATION=Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia> <TARGET=BIRC5; FLT3; TERT; BCR; ABL1>"
Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,[15*]C1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,"<INDICATION=Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia> <TARGET=BIRC5; FLT3; TERT; BCR; ABL1>"
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[1*]C(=O)C=C,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[16*]c1cc([16*])c([16*])cc1[16*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N[5*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[14*]c1ccnc([14*])n1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[16*]c1cn(C)c2ccccc12,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[3*]OC,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N([5*])C,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[4*]CC[4*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,[5*]N(C)C,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS>
Oxaliplatin,O=C(O)C(=O)O.[NH-]C1CCCCC1[NH-].[Pt+2],O=C(O)C(=O)O,<INDICATION=Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer> <TARGET=DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2>
Oxaliplatin,O=C(O)C(=O)O.[NH-]C1CCCCC1[NH-].[Pt+2],[NH-]C1CCCCC1[NH-],<INDICATION=Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer> <TARGET=DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2>
Oxaliplatin,O=C(O)C(=O)O.[NH-]C1CCCCC1[NH-].[Pt+2],[Pt+2],<INDICATION=Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer> <TARGET=DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(C)=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[15*]C1CC2(O)C([15*])C3C4([15*])COC4CC(O)C3(C)C(=O)C([15*])C(=C1C)C2(C)C,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(C)=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C([6*])=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[3*]O[3*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C(=O)C(O)C([4*])[8*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[5*]N[5*],<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[1*]C([6*])=O,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,[16*]c1ccccc1,<INDICATION=Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer> <TARGET=TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[8*]CC,<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[1*]C(=O)CC1=C2N=C(C=C3NC(=CC4=NC(=C(C)C4=[7*])C=C4N=C1C([15*])C4C)C(C)C3[15*])C(C)=C2C([O-])=NCCS(=O)(=O)O,<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[3*]OC,<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[7*]=C(C)[O-],<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[8*]CCC(=O)O,<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Padeliporfin,CCC1C2=CC3=NC(=C(CC(=O)OC)C4=NC(=CC5=C(C)C(=C(C)[O-])C(=N5)C=C(N2)C1C)C(C)C4CCC(=O)O)C(C([O-])=NCCS(=O)(=O)O)=C3C.[Pd+2],[Pd+2],<INDICATION=Low-Risk Prostate Cancer of the one lobe only> <TARGET=nan>
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[6*]C(C)=O,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[9*]n1c(=O)c([16*])c(C)c2cnc([14*])nc21,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[5*]N[5*],"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[14*]c1ccc([16*])cn1,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[5*]N1CCNCC1,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,[15*]C1CCCC1,"<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer> <TARGET=MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3>"
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[16*]c1c(C)[nH]c2ccccc12,<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[4*]CC[8*],<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[5*]N[5*],<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[4*]C[8*],<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[7*]=Cc1ccc([16*])cc1,<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(=O)NO)cc1,[7*]=CC(=O)NO,<INDICATION=Refractory Multiple Myeloma> <TARGET=HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A>
Pazopanib,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,[16*]c1ccc(C)c(S(N)(=O)=O)c1,<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pazopanib,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pazopanib,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,[14*]c1ccnc([14*])n1,<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pazopanib,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,[5*]N([5*])C,<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pazopanib,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,[16*]c1ccc2c(C)n(C)nc2c1,<INDICATION=Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer> <TARGET=VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2>
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[16*]c1c[nH]c2nc(N)[nH]c(=O)c12,"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[8*]CC[8*],"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[16*]c1ccc([16*])cc1,"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[1*]C([6*])=O,"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[5*]N[5*],"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemetrexed,Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,[4*]C(CCC(=O)O)C(=O)O,"<INDICATION=Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma> <TARGET=RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[10*]N1Cc2cnc3[nH]c([14*])cc3c2N(CC)C1=O,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[16*]c1cc([16*])c(F)c([16*])c1F,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[3*]OC,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[3*]OC,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[4*]C[8*],"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pemigatinib,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,[5*]N1CCOCC1,"<INDICATION=Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas> <TARGET=FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1>"
Pentostatin,OCC1OC(n2cnc3c2NC=NCC3O)CC1O,[8*]CO,"<INDICATION=B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome> <TARGET=CCR1; PRKAA1; ADA>"
Pentostatin,OCC1OC(n2cnc3c2NC=NCC3O)CC1O,[13*]C1CC(O)C([13*])O1,"<INDICATION=B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome> <TARGET=CCR1; PRKAA1; ADA>"
Pentostatin,OCC1OC(n2cnc3c2NC=NCC3O)CC1O,[9*]n1cnc2c1NC=NCC2O,"<INDICATION=B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome> <TARGET=CCR1; PRKAA1; ADA>"
Pipobroman,O=C(CCBr)N1CCN(C(=O)CCBr)CC1,[1*]C(=O)CCBr,<INDICATION=nan> <TARGET=NFE2L2; KDM4E; ALDH1A1>
Pipobroman,O=C(CCBr)N1CCN(C(=O)CCBr)CC1,[5*]N1CCN([5*])CC1,<INDICATION=nan> <TARGET=NFE2L2; KDM4E; ALDH1A1>
Pipobroman,O=C(CCBr)N1CCN(C(=O)CCBr)CC1,[1*]C(=O)CCBr,<INDICATION=nan> <TARGET=NFE2L2; KDM4E; ALDH1A1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[3*]OC,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1c([16*])cccc1C3=O,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[6*]C(=O)CO,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[13*]C1CC(N)C([15*])C(C)O1,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[3*]O[3*],<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirarubicin,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(OC2CCCCO2)C(C)O1,[13*]C1CCCCO1,<INDICATION=nan> <TARGET=ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1>
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[3*]OC,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[16*]c1ccc(F)cc1[16*],"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[1*]C([6*])=O,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[5*]N[5*],"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[4*]C[8*],"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[16*]c1ccc([16*])cc1,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[9*]n1nc([14*])c([16*])c1N,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[8*]C(C)C(F)(F)F,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pirtobrutinib,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn(C(C)C(F)(F)F)c(N)c2C(N)=O)cc1,[6*]C(N)=O,"<INDICATION=Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma> <TARGET=BTK; TP53; EFNB2; IGH>"
Pixantrone,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,[4*]CCN,"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pixantrone,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,[5*]N[5*],"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pixantrone,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,[16*]c1ccc([16*])c2c1C(=O)c1ccncc1C2=O,"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pixantrone,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,[5*]N[5*],"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pixantrone,NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,[4*]CCN,"<INDICATION=Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma> <TARGET=TOP2A>"
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,[10*]N1C(=O)c2cccc(N)c2C1=O,<INDICATION=Refractory Multiple Myeloma> <TARGET=CRBN; RBX1; CUL4A; DDB1>
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,[15*]C1CCC(=O)NC1=O,<INDICATION=Refractory Multiple Myeloma> <TARGET=CRBN; RBX1; CUL4A; DDB1>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[16*]c1ccc(C)c(C#Cc2cnc3cccnn23)c1,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[1*]C([6*])=O,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[5*]N[5*],<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[16*]c1ccc([16*])c([16*])c1,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[4*]C[8*],<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[5*]N1CCN(C)CC1,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Ponatinib,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,[8*]C(F)(F)F,<INDICATION=Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia> <TARGET=FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[8*]CC([8*])CC#C,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[14*]c1cnc2nc(N)nc(N)c2n1,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[1*]C([6*])=O,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[5*]N[5*],<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralatrexate,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,[4*]C(CCC(=O)O)C(=O)O,<INDICATION=Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified> <TARGET=DHFR; PDF; RFC1>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[3*]OC,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[15*]C1CCC([15*])([15*])CC1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[1*]C([6*])=O,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[5*]N[5*],<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[4*]C([8*])C,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[14*]c1ccc([16*])cn1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[9*]n1cc(F)cn1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[14*]c1cc(C)nc([14*])n1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[5*]N[5*],<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Pralsetinib,COC1(C(=O)NC(C)c2ccc(-n3cc(F)cn3)nc2)CCC(c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,[14*]c1cc(C)[nH]n1,<INDICATION=Metastatic RET-fusion Non Small Cell Lung Cancer> <TARGET=EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET>
Prednisolone,CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,[15*]C1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3C(O)CC21C,"<INDICATION=Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF)> <TARGET=LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX>"
Prednisolone,CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,[6*]C(=O)CO,"<INDICATION=Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF)> <TARGET=LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX>"
Prednisone,CC12C=CC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO,[15*]C1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3C(=O)CC21C,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF)> <TARGET=BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19>"
Prednisone,CC12C=CC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO,[6*]C(=O)CO,"<INDICATION=Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF)> <TARGET=BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19>"
Procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,[8*]CNNC,<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,[1*]C([6*])=O,<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,[5*]N[5*],<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,[4*]C(C)C,<INDICATION=Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease> <TARGET=CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[8*]C(C)(C)C,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[14*]c1cc([14*])on1,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[5*]N[5*],<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[1*]C([1*])=O,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[5*]N[5*],<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[16*]c1ccc([16*])cc1,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[14*]c1cn2c(n1)sc1cc([16*])ccc12,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[3*]O[3*],<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[4*]CC[4*],<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,[5*]N1CCOCC1,<INDICATION=Newly Diagnosed Acute Myeloid Leukemia (AML)> <TARGET=DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[16*]c1ccc2nc(C)[nH]c(=O)c2c1,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[4*]C[8*],<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[5*]N([5*])C,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[14*]c1ccc([14*])s1,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[1*]C([6*])=O,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[5*]N[5*],<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Raltitrexed,Cc1nc2ccc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1,[4*]C(CCC(=O)O)C(=O)O,<INDICATION=Advanced Colorectal Cancer; Pleural Mesotheliomas> <TARGET=CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR>
Ranimustine,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,[3*]OC,<INDICATION=nan> <TARGET=nan>
Ranimustine,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,[13*]C1OC([13*])C(O)C(O)C1O,<INDICATION=nan> <TARGET=nan>
Ranimustine,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,[4*]C[8*],<INDICATION=nan> <TARGET=nan>
Ranimustine,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,[5*]N[5*],<INDICATION=nan> <TARGET=nan>
Ranimustine,COC1OC(CNC(=O)N(CCCl)N=O)C(O)C(O)C1O,[1*]C(=O)N(CCCl)N=O,<INDICATION=nan> <TARGET=nan>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[5*]NC,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[1*]C([6*])=O,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[14*]c1cc([16*])ccn1,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[3*]O[3*],<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[16*]c1ccc([16*])c(F)c1,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[5*]N[5*],<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[1*]C([1*])=O,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[5*]N[5*],<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[16*]c1ccc(Cl)c([16*])c1,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,[8*]C(F)(F)F,<INDICATION=Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor> <TARGET=PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[1*]C(=O)NOC,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[9*]n1c(=O)c2c([16*])c([14*])sc2n([9*])c1=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[4*]C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[5*]N(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[14*]c1ccc([14*])nn1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[3*]OC,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[8*]C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Relugolix,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,[16*]c1c(F)cccc1F,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; LHCGR>
Repotrectinib,CC1CNC(=O)c2cnn3ccc(nc23)NC(C)c2cc(F)ccc2O1,CC1CNC(=O)c2cnn3ccc(nc23)NC(C)c2cc(F)ccc2O1,<INDICATION=locally active or metastatic non-small cell lung cancer> <TARGET=EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[5*]N(C)C,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[1*]C([6*])=O,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[9*]n1c([14*])cc2cnc([14*])nc21,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[5*]N[5*],<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[14*]c1ccc([16*])cn1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[5*]N1CCNCC1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,[15*]C1CCCC1,<INDICATION=Advanced Breast Cancer; Metastatic Breast Cancer> <TARGET=CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[8*]CC,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[9*]n1c(=O)c([16*])cc2cnc([14*])cc21,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[16*]c1cc([16*])c(Br)cc1F,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[5*]N[5*],<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[1*]C([1*])=O,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[5*]N[5*],<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[16*]c1ccccc1,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Ripretinib,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,[5*]NC,<INDICATION=Advanced Gastrointestinal Stromal Tumor (GIST)> <TARGET=CYP3A4; KIT; PDGFRB; PDGFRA; DPT>
Romidepsin,CC=C1NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,[7*]=CC,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7>
Romidepsin,CC=C1NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,[7*]=C1NC(=O)C2CSSCCC=CC(CC(=O)NC([13*])C(=O)N2)OC(=O)C([13*])NC1=O,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7>
Romidepsin,CC=C1NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,[8*]C(C)C,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7>
Romidepsin,CC=C1NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,[8*]C(C)C,<INDICATION=Refractory peripheral cutaneous T-cell lymphoma> <TARGET=BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7>
Rucaparib,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,[5*]NC,<INDICATION=Advanced Ovarian Cancer> <TARGET=PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2>
Rucaparib,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,[4*]C[8*],<INDICATION=Advanced Ovarian Cancer> <TARGET=PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2>
Rucaparib,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Advanced Ovarian Cancer> <TARGET=PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2>
Rucaparib,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,[14*]c1[nH]c2cc(F)cc3c2c1CCNC3=O,<INDICATION=Advanced Ovarian Cancer> <TARGET=PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2>
Ruxolitinib,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,[8*]C([8*])CC#N,<INDICATION=Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera> <TARGET=JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3>
Ruxolitinib,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,[15*]C1CCCC1,<INDICATION=Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera> <TARGET=JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3>
Ruxolitinib,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,[9*]n1cc([16*])cn1,<INDICATION=Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera> <TARGET=JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3>
Ruxolitinib,N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,[14*]c1ncnc2[nH]ccc12,<INDICATION=Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera> <TARGET=JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[8*]CC,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]C1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[16*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[1*]C([1*])=O,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]C[8*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[16*]c1ccc([16*])cc1,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[5*]N[5*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[1*]C(=O)C([4*])CCCCN,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[5*]N[5*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[1*]C(=O)C[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[1*]C(=O)C[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[5*]N[5*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[4*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[3*]O[3*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC[8*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[9*]n1cc([14*])nn1,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]C[8*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[5*]N[5*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[1*]C([6*])=O,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[15*]C1CCC([15*])CC1,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[8*]C[8*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[10*]N1C(=O)CC([15*])C1=O,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[11*]S[11*],<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Sacituzumab Govitecan,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(CC)OC(=O)OCc1ccc(NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCn2cc(CNC(=O)C3CCC(CN4C(=O)CC(SCC(N)C(=O)O)C4=O)CC3)nn2)cc1,[4*]CC(N)C(=O)O,<INDICATION=Metastatic Triple-negative Breast Cancer> <TARGET=ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2>
Selinexor,O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,[14*]c1ncn(C=CC(=O)NNc2cnccn2)n1,<INDICATION=Refractory Multiple Myeloma> <TARGET=FLT3; TET2; TP53; XPO1; H2AX>
Selinexor,O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,[16*]c1cc([16*])cc([16*])c1,<INDICATION=Refractory Multiple Myeloma> <TARGET=FLT3; TET2; TP53; XPO1; H2AX>
Selinexor,O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,[8*]C(F)(F)F,<INDICATION=Refractory Multiple Myeloma> <TARGET=FLT3; TET2; TP53; XPO1; H2AX>
Selinexor,O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,[8*]C(F)(F)F,<INDICATION=Refractory Multiple Myeloma> <TARGET=FLT3; TET2; TP53; XPO1; H2AX>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[3*]OC,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[14*]c1ccc([16*])cn1,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[4*]C[8*],<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[5*]N1CC2CC(C1)N2[5*],<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[14*]c1ccc([16*])cn1,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[16*]c1cc([16*])c2c(C#N)cnn2c1,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[3*]O[3*],<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Selpercatinib,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,[4*]CC(C)(C)O,<INDICATION=Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer> <TARGET=RET; KIF5B; PTK2B; CCDC6>
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[16*]c1cccc([16*])c1C,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[1*]C([6*])=O,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[5*]N[5*],"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[14*]c1ccc([16*])cn1,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[5*]N1CC(C)OC(C)C1,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[16*]c1ccc([16*])cc1,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sonidegib,Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,[3*]OC(F)(F)F,"<INDICATION=Refractory, locally advanced Basal cell carcinoma> <TARGET=PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN>"
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[5*]NC,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[1*]C([6*])=O,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[14*]c1cc([16*])ccn1,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[3*]O[3*],<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[16*]c1ccc([16*])cc1,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[1*]C([1*])=O,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[16*]c1ccc(Cl)c([16*])c1,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,[8*]C(F)(F)F,<INDICATION=Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma> <TARGET=DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7>
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[1*]C(=O)C=C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[5*]N1CCN([5*])C(C)C1,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[9*]n1c(=O)nc([14*])c2cc(F)c([14*])nc21,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[14*]c1nccc(C)c1[16*],"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[8*]C(C)C,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Sotorasib,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,[16*]c1c(O)cccc1F,"<INDICATION=Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer> <TARGET=KRAS; HRAS; NRAS>"
Streptozocin,CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O,[1*]C(=O)N(C)N=O,<INDICATION=Stage 4 islet cell carcinoma> <TARGET=SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3>
Streptozocin,CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O,[5*]N[5*],<INDICATION=Stage 4 islet cell carcinoma> <TARGET=SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3>
Streptozocin,CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O,[13*]C1OC(O)C([15*])C(O)C1O,<INDICATION=Stage 4 islet cell carcinoma> <TARGET=SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3>
Streptozocin,CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O,[8*]CO,<INDICATION=Stage 4 islet cell carcinoma> <TARGET=SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3>
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[4*]CC,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[5*]N([5*])[5*],"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[4*]CC,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[4*]CC[4*],"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[5*]N[5*],"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[1*]C([6*])=O,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[7*]=Cc1[nH]c(C)c([16*])c1C,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C,[7*]=C1C(=O)Nc2ccc(F)cc21,"<INDICATION=Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors> <TARGET=FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1>"
Talazoparib,Cn1ncnc1C1c2n[nH]c(=O)c3cc(F)cc(c23)NC1c1ccc(F)cc1,[13*]C1Nc2cc(F)cc3c(=O)[nH]nc(c23)C1c1ncnn1C,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN>
Talazoparib,Cn1ncnc1C1c2n[nH]c(=O)c3cc(F)cc(c23)NC1c1ccc(F)cc1,[16*]c1ccc(F)cc1,<INDICATION=Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer> <TARGET=MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN>
Tamoxifen,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,[7*]=C(CC)c1ccccc1,<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tamoxifen,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,[7*]=C(c1ccccc1)c1ccc([16*])cc1,<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tamoxifen,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,[3*]O[3*],<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tamoxifen,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,[4*]CC[4*],<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tamoxifen,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,[5*]N(C)C,<INDICATION=Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer> <TARGET=AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[4*]CC,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[5*]N([5*])[5*],<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[16*]c1cc([16*])c(C)c([16*])c1,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[16*]c1ccc([16*])cc1,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[4*]C[8*],<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[5*]N1CCOCC1,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[1*]C([6*])=O,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[5*]N[5*],<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[4*]C[8*],<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[16*]c1c(C)cc(C)[nH]c1=O,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Tazemetostat,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,[15*]C1CCOCC1,<INDICATION=Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma> <TARGET=SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A>
Temoporfin,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,[16*]c1cccc(O)c1,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temoporfin,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,[16*]c1c2nc(c([16*])c3ccc([nH]3)c([16*])c3nc(c([16*])c4ccc1[nH]4)CC3)C=C2,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temoporfin,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,[16*]c1cccc(O)c1,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temoporfin,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,[16*]c1cccc(O)c1,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temoporfin,Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1,[16*]c1cccc(O)c1,<INDICATION=Advanced Head and Neck Squamous Cell Carcinoma> <TARGET=nan>
Temozolomide,Cn1nnc2c(C(N)=O)ncn2c1=O,[14*]c1ncn2c(=O)n(C)nnc12,"<INDICATION=Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome> <TARGET=PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11>"
Temozolomide,Cn1nnc2c(C(N)=O)ncn2c1=O,[6*]C(N)=O,"<INDICATION=Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome> <TARGET=PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11>"
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[13*]C1CC(=O)C(C)C=C(C)C(O)C([15*])C(=O)C(C)CC(C)C=CC=CC=C(C)C([15*])CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)O1,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[8*]CC([8*])C,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[15*]C1CCC([15*])C([15*])C1,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]O[3*],<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[1*]C(=O)C(C)(CO)CO,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma> <TARGET=NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[15*]C1CCN(C)CC1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[4*]C[8*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[3*]O[3*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[14*]c1ncc([16*])cn1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[16*]c1cccc([16*])c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[8*]C[8*],<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[9*]n1nc([14*])ccc1=O,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Tepotinib,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,[16*]c1cccc(C#N)c1,<INDICATION=Metastatic Non-Small Cell Lung Cancer> <TARGET=MET; EGFR; DRD4; ALK>
Thalidomide,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,[15*]C1CCC(=O)NC1=O,<INDICATION=Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma> <TARGET=FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD>
Thalidomide,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,[10*]N1C(=O)c2ccccc2C1=O,<INDICATION=Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma> <TARGET=FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD>
Thioguanine,Nc1nc(=S)c2[nH]cnc2[nH]1,Nc1nc(=S)c2[nH]cnc2[nH]1,<INDICATION=Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia> <TARGET=KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4>
Thiotepa,S=P(N1CC1)(N1CC1)N1CC1,S=P(N1CC1)(N1CC1)N1CC1,<INDICATION=Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion> <TARGET=TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[16*]c1cc2nccc([16*])c2cc1[16*],<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[3*]O[3*],<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[16*]c1ccc([16*])c(Cl)c1,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[1*]C([1*])=O,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[5*]N[5*],<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[14*]c1cc(C)on1,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,[3*]OC,<INDICATION=Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma> <TARGET=FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3>
Topotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,[16*]c1c(O)ccc2nc3c(cc12)Cn1c-3cc2c(c1=O)COC(=O)C2(O)CC,"<INDICATION=Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer> <TARGET=DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16>"
Topotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,[4*]C[8*],"<INDICATION=Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer> <TARGET=DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16>"
Topotecan,CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,[5*]N(C)C,"<INDICATION=Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer> <TARGET=DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16>"
Toremifene,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,[5*]N(C)C,<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Toremifene,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,[4*]CC[4*],<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Toremifene,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,[3*]O[3*],<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Toremifene,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,[7*]=C(c1ccccc1)c1ccc([16*])cc1,<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Toremifene,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,[7*]=C(CCCl)c1ccccc1,<INDICATION=Desmoid Tumors; Metastatic Breast Cancer> <TARGET=CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80>
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[4*]C([8*])C,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[5*]N[5*],"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[1*]C([6*])=O,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[14*]c1ncnc(N)c1Cl,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[14*]c1cnc([14*])s1,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[1*]C([6*])=O,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[5*]N[5*],"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[14*]c1cc([16*])c(Cl)cn1,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Tovorafenib,CC(NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,[8*]C(F)(F)F,"<INDICATION=Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation> <TARGET=RAF1; BRAF; ARAF; EFNA2; ZHX2>"
Trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]OC,<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[16*]c1cc2c(cc1O)CCNC21CSC2c3c([16*])c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c([16*])c(O)c5C(C21)N3C)OCO4,<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]O[3*],<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[1*]C(C)=O,<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trabectedin,COc1cc2c(cc1O)CCNC21CSC2c3c(OC(C)=O)c(C)c4c(c3C(COC1=O)N1C(O)C3Cc5cc(C)c(OC)c(O)c5C(C21)N3C)OCO4,[3*]OC,<INDICATION=Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma> <TARGET=PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[1*]C(C)=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[16*]c1cccc([16*])c1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[9*]n1c(=O)c2c([14*])n(C)c(=O)c(C)c2n([9*])c1=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[15*]C1CC1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trametinib,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,[16*]c1ccc(I)cc1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation> <TARGET=ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7>
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]OC,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[15*]C1C=CC=C(C)Cc2cc([16*])c(Cl)c(c2)N(C)C(=O)CC([15*])C2(C)OC2C(C)C2CC1(O)NC(=O)O2,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]O[3*],"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[1*]C(=O)C([4*])C,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[5*]N([5*])C,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[1*]C(=O)CC[4*],"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[11*]S[11*],"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[10*]N1C(=O)CC([15*])C1=O,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[8*]C[8*],"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[15*]C1CCC([15*])CC1,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[6*]C(N)=O,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Trastuzumab Emtansine,COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSC1CC(=O)N(CC3CCC(C(N)=O)CC3)C1=O)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,[3*]OC,"<INDICATION=Refractory, metastatic Non small cell lung cancer> <TARGET=ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8>"
Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=[7*])C,<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC1=C(C)CCCC1(C)C,<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC=[7*],<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=[7*])C,<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Tretinoin,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,[7*]=CC(=O)O,<INDICATION=FAB classification M3 Acute promyelocytic leukemia> <TARGET=SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])CC(C)C,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[16*]c1c[nH]c2ccccc12,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[16*]c1ccc(O)cc1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])CO,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[16*]c1c[nH]c2ccccc12,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])C[8*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[14*]c1cnc[nH]1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[13*]C1CCC(=O)N1,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C(=O)C([4*])CCCN=C(N)N,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N1CCCC1[13*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[1*]C([6*])=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[5*]N[5*],<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Triptorelin,CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1cnc[nH]1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,[4*]CC(N)=O,<INDICATION=Advanced Prostate Cancer> <TARGET=GNRHR; STS>
Trofosfamide,O=P1(N(CCCl)CCCl)OCCCN1CCCl,O=P1(N(CCCl)CCCl)OCCCN1CCCl,<INDICATION=Non-Hodgkin's lymphoma> <TARGET=CYP2B6>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[16*]c1ccc([16*])c(C)c1,<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[5*]N[5*],<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[14*]c1ncnc2ccc([16*])cc12,<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[5*]NC1=NC(C)(C)CO1,<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[3*]O[3*],<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,[16*]c1ccn2ncnc2c1,<INDICATION=Breast Cancer; Unresectable Breast Cancer> <TARGET=ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[4*]C(C)C,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[3*]O[3*],<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[16*]c1ccc([16*])c(F)c1,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[9*]n1nc([14*])c2c(N)ncnc21,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[8*]C([8*])C,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[14*]c1oc2ccc(F)cc2c(=O)c1[16*],<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Umbralisib,CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,[16*]c1cccc(F)c1,<INDICATION=B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)> <TARGET=PIK3CD; PIK3CG; ELF2; F7>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[1*]C(=O)CCCC,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[3*]O[3*],<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[4*]CC([6*])=O,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[3*]OC1CC([15*])(O)Cc2c(O)c3c(c(O)c21)C(=O)c1c([16*])cccc1C3=O,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[13*]C1CC([15*])C(O)C(C)O1,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[5*]N[5*],<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[1*]C(=O)C(F)(F)F,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Valrubicin,CCCCC(=O)OCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O,[3*]OC,<INDICATION=In situ BCG-refractory Bladder carcinoma> <TARGET=TOP2A; AR>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[3*]OC,<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[14*]c1ncnc2cc([16*])c([16*])cc12,<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[5*]N[5*],<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[16*]c1ccc(Br)cc1F,<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[3*]O[3*],<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[4*]C[8*],<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,[15*]C1CCN(C)CC1,<INDICATION=Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer> <TARGET=KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[12*]S(=O)(=O)CCC,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[5*]N[5*],<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[16*]c1ccc(F)c([16*])c1F,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[6*]C([6*])=O,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[16*]c1cnc2[nH]cc([16*])c2c1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,[16*]c1ccc(Cl)cc1,<INDICATION=Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer> <TARGET=CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[4*]CC1=C(c2ccc(Cl)cc2)CC(C)(C)CC1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[5*]N1CCN([5*])CC1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[16*]c1ccc([16*])c([16*])c1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[1*]C([6*])=O,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[5*]N[5*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[12*]S(=O)(=O)c1ccc([16*])c([N+](=O)[O-])c1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[5*]N[5*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[4*]C[8*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[15*]C1CCOCC1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[3*]O[3*],<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Venetoclax,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,[16*]c1cnc2[nH]ccc2c1,<INDICATION=Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma> <TARGET=IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1>
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C(=O)C1(c2cc3c(cc2[16*])N(C)C2C([15*])(O)C([15*])C4([15*])C=CCN5CCC32C54)CC2CN(CCc3c1[nH]c1ccccc31)CC([15*])(O)C2,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C([6*])=O,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]O[3*],"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C(C)=O,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vinblastine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer> <TARGET=TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C(=O)C1(c2cc3c(cc2[16*])N(C=O)C2C([15*])(O)C([15*])C4([15*])C=CCN5CCC32C54)CC2CN(CCc3c1[nH]c1ccccc31)CC([15*])(O)C2,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C([6*])=O,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]O[3*],"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C(C)=O,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vincristine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma> <TARGET=NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[1*]C(=O)C1(c2cc3c(cc2[16*])N(C)C2C([15*])(O)C(O)C4([15*])C=CCN5CCC32C54)CC2CN(CCc3c1[nH]c1ccccc31)CC([15*])(O)C2,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[3*]OC,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[6*]C(N)=O,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vindesine,CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,[8*]CC,"<INDICATION=Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant> <TARGET=TUBB; ABCB1; TUBB1; CYP3A4>"
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[8*]CC,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[1*]C(=O)C1(c2cc3c(cc2[16*])N(C)C2C([15*])(O)C([15*])C4([15*])C=CCN5CCC32C54)CC2CC([15*])CN(Cc3c1[nH]c1ccccc31)C2,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[3*]OC,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[8*]C(C)(F)F,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[3*]OC,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[1*]C([6*])=O,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[3*]OC,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[3*]O[3*],<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinflunine,CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,[1*]C(C)=O,<INDICATION=Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract> <TARGET=TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B>
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[1*]C(=O)C1(c2cc3c(cc2[16*])N(C)C2C([15*])(O)C([15*])C4([15*])C=CCN5CCC32C54)CC2C=C(CC)CN(Cc3c1[nH]c1ccccc31)C2,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[3*]OC,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[3*]OC,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[1*]C([6*])=O,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[3*]OC,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[3*]O[3*],"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[1*]C(C)=O,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vinorelbine,CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,[8*]CC,"<INDICATION=Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer> <TARGET=TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8>"
Vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,[16*]c1ccc(S(C)(=O)=O)cc1Cl,<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,[1*]C([6*])=O,<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,[5*]N[5*],<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,[16*]c1ccc(Cl)c([16*])c1,<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,[14*]c1ccccn1,<INDICATION=Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma> <TARGET=SMO; PTCH1; SHH; ALOX12>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[4*]C(C)C(F)(F)F,<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[5*]N[5*],<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[14*]c1nc([14*])nc([14*])n1,<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[5*]N[5*],<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[4*]C(C)C(F)(F)F,<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorasidenib,CC(Nc1nc(NC(C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,[14*]c1cccc(Cl)n1,<INDICATION=Grade 2 astrocytoma or oligodendroglioma> <TARGET=IDH1; IDH2; GRB2; GPX1P2>
Vorinostat,O=C(CCCCCCC(=O)Nc1ccccc1)NO,[1*]C(=O)CCCCCCC(=O)NO,<INDICATION=Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma> <TARGET=TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A>
Vorinostat,O=C(CCCCCCC(=O)Nc1ccccc1)NO,[5*]N[5*],<INDICATION=Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma> <TARGET=TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A>
Vorinostat,O=C(CCCCCCC(=O)Nc1ccccc1)NO,[16*]c1ccccc1,<INDICATION=Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma> <TARGET=TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[1*]C(=O)C=C,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[5*]N1CCC(C2CCNc3c([16*])c([14*])nn32)CC1,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[6*]C(N)=O,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[16*]c1ccc([16*])cc1,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[3*]O[3*],<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
Zanubrutinib,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,[16*]c1ccccc1,<INDICATION=Mantle Cell Lymphoma (MCL)> <TARGET=TP53; BTK; EFNB2; MYD88>
